SCHEMBL282471

SCHEMBL282471

O=C(Cl)c1ccc(SC(F)(F)F)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.49
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
KCNK2 O95069 10/20 0.47
KCNK10 P57789 8/20 0.47
KIF11 P52732 1/20 0.46
EPHX2 P34913 1/20 0.45
NR1H4 Q96RI1 1/20 0.45
PTPRZ1 P23471 2/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
PTPN1 P18031 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10919991 0.83 LMNA (0.53) TRPV1ALDH1A1KDM4ETDP1KCNK2
SCHEMBL10743419 0.81 ALDH1A1 (0.35) TRPV1ALDH1A1KDM4ETDP1KCNK2
SCHEMBL1015553 0.81 KCNK2 (0.57) TRPV1ALDH1A1KDM4ETDP1KCNK2
SCHEMBL10740573 0.81 ALDH1A1 (0.50) TRPV1ALDH1A1KDM4ETDP1KCNK2
SCHEMBL2541283 0.79 KIF11 (0.54) TRPV1ALDH1A1KDM4ETDP1KCNK2
SCHEMBL1160810 0.79 HPGD (0.59) TRPV1ALDH1A1KDM4ETDP1KCNK2
SCHEMBL11451464 0.79 ALDH1A1 (0.44) TRPV1ALDH1A1KDM4EEPHX2NR1H4
SCHEMBL8005997 0.79 KCNK2 (0.54) TRPV1ALDH1A1KDM4ETDP1KCNK2
SCHEMBL1448525 0.77 TSHR (0.49) TRPV1ALDH1A1KCNK2KCNK10NPC1
SCHEMBL11106674 0.76 KCNK2 (0.51) TRPV1ALDH1A1KDM4ETDP1KCNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12209094-B2 CCR2 receptor antagonists and uses thereof CENTREXION THERAPEUTICS CORPORATION (US) 2025-01-28 US disclosed
US-20240109909-A1 CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT 2024-04-04 US disclosed
US-11773066-B2 Indazolylcyanoethylamino compound, compositions of same, method of making, and methods of using thereof Boehringer Ingelheim Animal Health USA Inc. (US) 2023-10-03 US disclosed
US-20230278955-A1 VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF UNIV KYOTO (JP) 2023-09-07 US disclosed
US-11731981-B2 CCR2 receptor antagonists and uses thereof CENTREXION THERAPEUTICS CORPORATION (US) 2023-08-22 US disclosed
US-20220017473-A1 INDAZOLYLCYANOETHYLAMINO COMPOUND, COMPOSITIONS OF SAME, METHOD OF MAKING, AND METHODS OF USING THEREOF Boehringer Ingelheim Animal Health USA Inc. (US) 2022-01-20 US disclosed
US-20220002310-A1 CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT 2022-01-06 US disclosed
EP-3883648-A1 INDAZOLYLCYANOETHYLAMINO COMPOUND, COMPOSITIONS OF SAME, METHOD OF MAKING, AND METHODS OF USING THEREOF Boehringer Ingelheim Animal Health USA Inc. (US) 2021-09-29 EP disclosed
CN-113260419-A Indazolyl cyanoethylamino compounds, compositions thereof, methods of making the same, and methods of using the same 勃林格殷格翰动物保健美国公司 2021-08-13 CN disclosed
WO-2021149818-A1 COMBINATION AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER 国立大学法人東京農工大学 2021-07-29 WO disclosed
US-4122281-A DIURETIC, SALURETIC, ANTIHYPERTENSIVE BAYER AKTIENGESELLSCHAFT (DE) 1978-10-24 US disclosed
US-4117145-A DIURETIC, HYPOTENSIVE, ANTITHROMBOTIC AGENTS BAYER AKTIENGESELLSCHAFT (DE) 1978-09-26 US disclosed
US-4117143-A USED AS ANTITHROMBOTIC AGENTS BAYER AKTIENGESELLSCHAFT (DE) 1978-09-26 US disclosed
US-4113957-A DIURETIC, SALURETIC, HYPOTENSIVE, ANTITHROMBOTIC BAYER AKTIENGESELLSCHAFT (DE) 1978-09-12 US disclosed
US-4113872-A DIURETICS, SALURETICS, ANTIHYPERTENSIVE, ANTITHROMBOTIC AGENTS BAKER AKTIENGESELLSHAFT (DE) 1978-09-12 US disclosed
US-4112109-A DIURETIC, SALURETIC, ANTIHYPERTENSIVE, ANTITHROMBOTIC BAYER AKTIENGESELLSCHAFT (DE) 1978-09-05 US disclosed
US-4099011-A DIURETIC, SALURETIC, HYPOTENSIVE, ANTITHROMBOTIC BAYER AKTIENGESELLSCHAFT (DE) 1978-07-04 US disclosed
US-4096152-A DIURETICS, SALURETICS, HYPOTENSIVE BAYER AKTIENGESELLSCHAFT (DT) 1978-06-20 US disclosed
US-4069334-A DIURETICS, HYPOTENSIVES BAYER AKTIENGESELLSCHAFT (DT) 1978-01-17 US disclosed
US-4002641-A DIURETICS, SALURETICS, HYPOTENSIVES BAYER AKTIENGESELLSCHAFT (DT) 1977-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731981-B2 CCR2 receptor antagonists and uses thereof CCR2, CCRL2, CCR1 TRPV1 212/4885ALDH1A1 1767/4885KDM4E 4483/4885
US-20230278955-A1 VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF VDR, CYP24A1, CYP2R1 TRPV1 2094/4885ALDH1A1 256/4885KDM4E 1757/4885
US-11773066-B2 Indazolylcyanoethylamino compound, compositions of same, method of making, and methods of using thereof ACHE, DDT, NOTUM TRPV1 2283/4885ALDH1A1 333/4885KDM4E 275/4885
US-20220017473-A1 INDAZOLYLCYANOETHYLAMINO COMPOUND, COMPOSITIONS OF SAME, METHOD OF MAKING, AND METHODS OF USING THEREOF ACHE, DDT, NOTUM TRPV1 2283/4885ALDH1A1 333/4885KDM4E 275/4885
US-20240109909-A1 CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF CCR2, CCRL2, CCR1 TRPV1 212/4885ALDH1A1 1767/4885KDM4E 4483/4885
US-20220002310-A1 CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF CCR2, CCRL2, CCR1 TRPV1 212/4885ALDH1A1 1767/4885KDM4E 4483/4885
US-12209094-B2 CCR2 receptor antagonists and uses thereof CCR2, CCRL2, CCR1 TRPV1 212/4885ALDH1A1 1767/4885KDM4E 4483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.